Aklief (Trifarotene) Patent Expiration, LOE Window & CMS Spending
Aklief (Trifarotene) by Galderma Laboratories: FDA Orange Book core substance LOE 2031-07-19 (last listed 2033-05-30), 0 AB generics, $334K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Galderma Laboratories |
| FDA Application & Pathway | N211527 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-07-19 |
| Last Listed Patent or Exclusivity Date | 2033-05-30 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $334K |
| 2024 Medicare Part D Spend | $260K |
| 2024 Medicaid Spend | $74K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |